MedImmune

MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca and is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease.

Address: Milstein Building, Granta Park , Cambridge
Postcode: CB21 6GH
Country: United Kingdom
Website: http://www.medimmune.com
Membership type:Founder Member

MedImmune is the global biologics research and development arm of AstraZeneca with candidate biologics and vaccines that currently compromise approximately 50 per cent of AstraZeneca’s overall R&D pipeline.   It has one of the most robust and promising pipelines in the biologics industry, with more than 120 biologics in research and development and over 40 projects in clinical stage development.

MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease. In addition, the company is opportunistic in infectious disease and vaccines. Approximately 2,200 full-time employees are in the US and UK. MedImmune is headquartered in Gaithersburg, MD – one of AstraZeneca’s three global R&D centres, along with Cambridge, UK and MoIndal, Sweden

MedImmune’s Cambridge team is focused on the research and early development of our biologics portfolio. MedImmune has built on the local legacy of Cambridge Antibody Technology (CAT) – acquired by AstraZeneca and integrated with MedImmune in 2007 – where three marketed products (Humira, Benlysta and raxibacumab) were invented.  With over 600 employees, MedImmune Cambridge has strong collaborative links with numerous academics, researchers, foundations and neighbouring companies in the largest biotech cluster in Europe and has an active outreach programme within the local community.

1 Humira is a registered trademark of AbbVie Inc.
2 Benlysta is a registered trademark of GlaxoSmithKline

MedImmune is the global biologics R&D arm of AstraZeneca

MedImmune is the global biologics research and development arm of AstraZeneca, focused on pioneering research and exploring novel mechanisms and pathways across key therapeutic areas.

Cancer Research UK & MedImmune open research centre in Cambridge

Cancer Research UK & MedImmune launch biotherapeutics research centre in Cambridge

A new laboratory that will focus on the discovery and development of novel biologic cancer treatments and diagnostics has been opened this week in Cambridge by life sciences minister George Freeman MP.

11 September 2015Read in full

MedImmune and Nobel media host Nobel Laureate Dr Randy Schekman on September 10th

MedImmune, the global biologics research and development arm of AstraZeneca, and Nobel Media, which shares inspirational stories of Nobel Laureates with a global audience, will host Nobel Laureate Dr. Randy Schekman on Thursday, Sept. 10th as part of the Nobel Prize Inspiration Initiative (NPII).

10 September 2015Read in full

MedImmune enters into strategic agreement with Inovio Pharmaceuticals

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licence agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.

10 August 2015Read in full

MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an exclusive clinical trial collaboration with Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer.

5 August 2015Read in full

Dr David Berman joins MedImmune as Head of Oncology

MedImmune, the global biologics research and development arm of AstraZeneca, announced that David Berman, MD, PhD, has joined the company as Head of the Oncology Innovative Medicines unit (iMED) and Senior Vice President.

22 July 2015Read in full

MedImmune collaborates on cell factory engineering science with University of Sheffield

MedImmune, the global biologics research and development arm of AstraZeneca, and the University of Sheffield announced today that they have entered into a multi-project research collaboration to generate breakthrough research in cell factory technology, the process by which living cells can be controlled and manipulated to make specific proteins with therapeutic benefits.

22 July 2015Read in full

MedImmune appoints new head of cardiovascular and metabolic disease reseearch

MedImmune, the global biologics research and development arm of AstraZeneca, has announced that Christopher Rhodes, PhD, has joined the company as Vice President, Cardiovascular and Metabolic Disease (CVMD) Research.

15 July 2015Read in full

MedImmune and University of Cambridge strengthen partnership

MedImmune, the global biologics research and development arm of AstraZeneca, and the University of Cambridge have announced a new five-year, multi-project collaboration with the University’s Department of Chemical Engineering and Biotechnology (CEB).

27 May 2015Read in full

MedImmune and Juno Therapeutics announce immuno-oncology clinical trial collaboration

MedImmune, the global biologics research and development arm of AstraZeneca, and Juno Therapeutics, Inc., a biopharmaceutical company focused on re-engaging the body's immune system to revolutionise the treatment of cancer, announced today that they have entered into a new collaboration.

23 April 2015Read in full

Medmmune & Immunocore collaborate to conduct immuno-oncology combination trials in melanoma

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a collaboration to conduct clinical trials in immuno-oncology with Immunocore Limited, a privately-held UK-based biotechnology company.

16 April 2015Read in full

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6